Comparative Pharmacology
Head-to-head clinical analysis: ANDROGEL versus TREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROGEL versus TREST.
ANDROGEL vs TREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.
Mirtazapine is a tetracyclic antidepressant that acts as a potent antagonist of central α2-adrenergic autoreceptors and heteroreceptors, leading to increased norepinephrine and serotonin neurotransmission. It also antagonizes 5-HT2 and 5-HT3 receptors, with no significant effect on serotonin reuptake.
50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.
10-15 mg orally every 6 hours as needed for agitation in dementia; maximum 60 mg/day.
None Documented
None Documented
The terminal elimination half-life of testosterone from AndroGel is approximately 10-12 hours when applied topically, but due to continuous absorption from the skin depot, serum levels are sustained over 24 hours, allowing once-daily dosing.
Terminal elimination half-life: 4–6 hours (clinically, dosing every 6–8 hours maintains therapeutic levels).
Approximately 90% of a topical dose is excreted in urine as conjugated and unconjugated metabolites, with about 6% excreted in feces via bile; renal elimination is the primary route.
Renal: 80% unchanged; biliary/fecal: 10% as metabolites; 10% other.
Category C
Category C
Androgen
Androgen